Invesco Ltd. Reduces Stock Holdings in Bruker Co. (NASDAQ:BRKR)

Invesco Ltd. decreased its holdings in Bruker Co. (NASDAQ:BRKR - Free Report) by 73.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 274,838 shares of the medical research company's stock after selling 767,326 shares during the quarter. Invesco Ltd. owned approximately 0.18% of Bruker worth $16,111,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in BRKR. Eagle Bay Advisors LLC grew its holdings in Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock worth $41,000 after acquiring an additional 674 shares during the period. UMB Bank n.a. boosted its stake in Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after acquiring an additional 248 shares in the last quarter. GAMMA Investing LLC grew its holdings in Bruker by 47.5% in the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock worth $75,000 after purchasing an additional 412 shares during the period. Quadrant Capital Group LLC increased its stake in Bruker by 18.2% in the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after purchasing an additional 196 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Bruker by 41.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock worth $78,000 after purchasing an additional 390 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Price Performance

BRKR stock traded up $1.04 during mid-day trading on Thursday, reaching $38.93. 1,102,170 shares of the company traded hands, compared to its average volume of 2,038,109. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. Bruker Co. has a 52-week low of $34.10 and a 52-week high of $82.04. The company has a market capitalization of $5.90 billion, a P/E ratio of 51.23, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a fifty day moving average price of $43.68 and a 200-day moving average price of $53.14.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. As a group, analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend was Monday, March 17th. Bruker's dividend payout ratio is presently 26.32%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on BRKR shares. Stifel Nicolaus decreased their price objective on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a report on Friday, February 14th. Guggenheim restated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Wells Fargo & Company dropped their price target on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Citigroup decreased their target price on Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Finally, Barclays cut their price target on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $65.00.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.